(Q38051705)

27 August 2017

title

Drug choices in autoimmune hepatitis: part A--Steroids (English)

1 reference

27 August 2017

1 reference

Albert J Czaja

1

1 reference

27 August 2017

publication date

1 September 2012

1 reference

Expert Review of Gastroenterology & Hepatology

27 August 2017

published in

1 reference

27 August 2017

volume

6

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

603-615

1 reference

Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis

27 August 2017

cites work

1 reference

Diagnosis and management of autoimmune hepatitis

21 January 2018

1 reference

Therapy of autoimmune hepatitis

21 January 2018

1 reference

Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy

21 January 2018

1 reference

Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis

21 January 2018

1 reference

Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis

21 January 2018

1 reference

Advances in the current treatment of autoimmune hepatitis

21 January 2018

1 reference

Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis

21 January 2018

1 reference

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience

21 January 2018

1 reference

Rapidity of treatment response and outcome in type 1 autoimmune hepatitis

21 January 2018

1 reference

Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance

21 January 2018

1 reference

Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

Transplantation for autoimmune hepatitis

21 January 2018

1 reference

Liver transplantation for autoimmune hepatitis: a single-center experience.

21 January 2018

1 reference

Long-term outcome of liver transplantation for autoimmune hepatitis

21 January 2018

1 reference

Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal

21 January 2018

1 reference

De novo autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

Autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared

21 January 2018

1 reference

Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis

21 January 2018

1 reference

Current and future treatments of autoimmune hepatitis

21 January 2018

1 reference

Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis

21 January 2018

1 reference

Treatment challenges and investigational opportunities in autoimmune hepatitis

21 January 2018

1 reference

Autoimmune hepatitis: the dilemma of rare diseases

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

21 January 2018

1 reference

Oral prednisone for chronic active liver disease: dose responses and bioavailability studies

21 January 2018

1 reference

Corticosteroid Pharmacokinetics in Liver Disease

21 January 2018

1 reference

11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids

21 January 2018

1 reference

11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase

21 January 2018

1 reference

Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors

21 January 2018

1 reference

Autoimmune hepatitis. Part A: pathogenesis

21 January 2018

1 reference

Understanding the pathogenesis of autoimmune hepatitis

21 January 2018

1 reference

High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes

21 January 2018

1 reference

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury

21 January 2018

1 reference

Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis

21 January 2018

1 reference

Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis

21 January 2018

1 reference

Structural determinants of P-glycoprotein-mediated transport of glucocorticoids

21 January 2018

1 reference

Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis

21 January 2018

1 reference

Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives

21 January 2018

1 reference

Budesonide in the treatment of inflammatory bowel disease

21 January 2018

1 reference

Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis

21 January 2018

1 reference

Budesonide in previously untreated autoimmune hepatitis.

21 January 2018

1 reference

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

Budesonide for the treatment of autoimmune hepatitis

21 January 2018

1 reference

Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome.

21 January 2018

1 reference

Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils

21 January 2018

1 reference

Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease

21 January 2018

1 reference

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

21 January 2018

1 reference

Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease

21 January 2018

1 reference

Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

21 January 2018

1 reference

Autoimmune hepatitis in special patient populations

21 January 2018

1 reference

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

21 January 2018

1 reference

Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis.

21 January 2018

1 reference

Treatment strategies in autoimmune hepatitis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EGH.12.40

1 reference

27 August 2017

1 reference